OBJECTIVE To study the maternal and fetal outcome of idiopathic thrombocytopenic purpura (ITP) in pregnancy. MATERIAL AND METHOD The medical records of women who were diagnosed to be idiopathic thrombocytopenic purpura during and before pregnancy from January 1995 to December 2004 were reviewed. RESULTS There were 33pregnancies from 29 ITP women as four women had two pregnancies each and on...

Metastatic duodenal adenocarcinoma is a rare disease, and it’s coexistence with idiopathic thrombocytopenic purpura is still very rare. Here we report first case of metastatic duodenal adenocarcinoma with coexistent ITP treated with palliative chemotherapy protocols. We initially managed ITP, after which having had a safe platelet count (above 75000/uL.), we safely administered chemotherapy pro...

Intracranial hemorrhage is the most fatal complication of idiopathic thrombocytopenic purpura(ITP) and is very rare(<1%) mostly in young females and intraparenchymal or subarachnoid in most of the cases. We report a case of 63 years of female presented with acute SDH with petechiae in both lower limbs and headache. After ruling out all causes patient was diagnosed as having idiopathic thrombocy...

Rituximab 375 mg/m(2) weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50 x 10(9)/L) and complete responses (platelet count > 100 x 10(9)/L) were achieved in 21/28 (75%) and 12/28 (43%) patients ...

PURPOSE OF REVIEW This review focuses on recent advances in the use of immune-based therapy to treat patients with refractory and relapsing acquired thrombotic thrombocytopenic purpura. RECENT FINDINGS Advances in understanding of the pathophysiology of idiopathic thrombotic thrombocytopenic purpura have provided the rationale for immune-based treatment approaches to refractory and relapsing ...